208.92USD+5.92%Mkt Cap: 30.84B $P/E: 22.441d ago
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple…
Industry Peers
Drug Manufacturers - General$1.04TUSDP/E 41.6
$601.73BUSDP/E 29.0
$449.42BUSDP/E 124.1
$305.83BUSDP/E 21.0
$315.22BUSDP/E 36.0
$272.16BUSDP/E 21.8
$268.42BUSDP/E 21.8
$243.51BUSDP/E 25.4
$216.37BUSDP/E 12.3
$212.87BUSDP/E 25.1
$200.54BUSDP/E 25.9
$169.23BUSDP/E 18.5
$143.28BUSDP/E 19.2
$123.57BUSDP/E 16.9
$100.10BUSDP/E 19.4
$85.16BUSDP/E 13.8
$50.96BUSD
MRV
Marvell Technology, Inc.$20.08BUSDP/E 7.4
$11.37BUSDP/E 22.7
$10.53BUSDP/E 18.3
$10.47BUSDP/E 18.2
$6.76BUSDP/E 15.0
$3.54BUSDP/E 14.5
$2.97BUSDP/E 18.1
$61.82MUSD
$39.24MUSD
ELXR
Elixxer Ltd.$9.51MUSD
FLXN
Horizon Flexible Income ETF—P/E 27.0
CELG-RI
Bristol-Myers Squibb Company Ce—
ROSE
DocMorris AG—
FR0000140022
SANOFITP29OCT49—
Indicators:|
Key Statistics
Company
Market Cap30.84B $
Enterprise Value33.12B $
Revenue (TTM)9.94B $
Gross Profit7.49B $
Net Income (TTM)1.29B $
Revenue/Share67.70 USD
Last Price208.92 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees7.5K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - General
ISINUS09062X1037
Valuation
P/E (Trailing)22.44
P/E (Forward)12.63
PEG4.04
EV/EBITDA9.36
EV/Revenue3.33
P/S3.10
P/B1.65
EPS (TTM)9.31
EPS (Forward)16.55
52W Range
121.0589% of range219.72
52W High219.72 USD
52W Low121.05 USD
Profitability
Gross Margin75.69%
Oper. Margin22.90%
EBITDA Margin35.62%
Profit Margin13.07%
ROE7.08%
ROA4.39%
Growth
Revenue Growth1.90%
Earnings Growth31.10%
Cash Flow & Leverage
Operating CF2.20B $
CapEx (TTM)235.40M $
FCF Margin19.43%
FCF Yield6.26%
Net Debt2.28B $
Net Debt/EBITDA0.64
Balance Sheet
Debt/Equity0.36
Current Ratio3.06
Quick Ratio2.02
Book Value/Sh126.37 USD
Cash/Share29.01 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split3:1
Split DateJan 18, 2001
Analyst Consensus
Rating1.9 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)225.45 USD
Upside (mean)+7.9%
Target Range157.00 USD – 300.00 USD
$157.00+7.9% to mean$300.00
# Analysts31
Ownership
Shares Out.147.64M
Float147.18M
Insiders0.19%
Institutions96.32%
Short Interest
Short Ratio5.0d
Short % Float4.32%
Short % Out.3.88%
Shares Short5.72M
Short (prev mo.)4.77M
Technical
SMA 50198.04 (+5.5%)
SMA 200180.04 (+16.0%)
Beta0.16
S&P 52W Chg20.25%
Avg Vol (30d)1.27M
Avg Vol (10d)1.76M
Technical Indicators
RSI (14)54.7
MACD1.3597
MACD Signal2.4617
MACD Hist.-1.1021
BB Upper219.95 USD
BB Middle204.16 USD
BB Lower188.38 USD
BB Width15.47%
ATR (14)8.973 USD
Vol Ratio (20d)1.28x